Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab
The Journal of Infectious Diseases · 17.01.2026 · 233 (1) · e212-e220
DOI: 10.1093/infdis/jiaf559 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 05.11.2025. Verfasst von Lisa Selzer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Virology, Gilead Sciences, Inc., Foster City, California, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc..
Abstract (Originalsprache)
Background
High rates of virologic suppression were observed in the Phase 1b study (NCT04811040) investigating lenacapavir and two broadly neutralizing antibodies (bNAb), teropavimab (30 mg/kg) and zinlirvimab (10 or 30 mg/kg), in virologically suppressed people with HIV-1 susceptible (IC90 ≤ 2 μg/mL) to both (primary cohort, n = 20) or either (pilot cohort, n = 10) bNAb. We describe resistance analyses through Week (W) 26.
Methods
Post-baseline resistance analyses were conducted at virologic failure, and exploratory resistance analyses performed for participants with virologic rebound. Low copy number genotyping methods for capsid and a 1 kb stretch of gp120 from rebound virus were developed, and phenotypic susceptibility assessed.
Results
Virologic failure was observed in 1/30 participants. This primary cohort participant had HIV RNA 155 copies/mL at W16 and developed Q67H in capsid (lenacapavir fold-change 4.7), without resistance to bNAbs; the participant resuppressed on oral antiretrovirals. Two pilot cohort participants, experienced virologic rebound at W26 (55 and 72 copies/mL) and restarted oral antiretrovirals. In exploratory analyses, neither had emergent lenacapavir resistance or altered bNAb susceptibility.
Conclusions
Lenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with rare emergent lenacapavir resistance and no bNAb resistance, supporting further Phase 2 evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Virology, Gilead Sciences, Inc., Foster City, California, USA.
- Bioinformatics, Gilead Sciences, Inc., Foster City, California, USA.
- Clinical Development, Gilead Sciences, Inc., Foster City, California, USA.
- Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
ORCID-Profile: Sally Demirdjian, Brie Falkard, Jiani Li, Ross Martin
Förderung
- Gilead Sciences, Inc.
Zitieren
APA
Selzer, L., Demirdjian, S., Falkard, B., Li, J., Martin, R., Collins, S. E., Eron, J., VanderVeen, L. A., & Callebaut, C. (2026). Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab. The Journal of Infectious Diseases, 233(1), e212-e220. https://doi.org/10.1093/infdis/jiaf559
Vancouver
Selzer L, Demirdjian S, Falkard B, Li J, Martin R, Collins SE, et al. Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab. The Journal of Infectious Diseases. 2026;233(1):e212-e220. doi:10.1093/infdis/jiaf559
BibTeX
@article{Selzer2026,
author = {Selzer, Lisa and Demirdjian, Sally and Falkard, Brie and Li, Jiani and Martin, Ross and Collins, Sean E and Eron, Joseph and VanderVeen, Laurie A and Callebaut, Christian},
title = {Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {233},
number = {1},
pages = {e212--e220},
doi = {10.1093/infdis/jiaf559}
}
EUVIMED